Navigate to
-
Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...
-
Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...
-
Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care
Prime Article: Perspectives -
Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication, you’ll find critical pharmacy trend insights that will help you make...
-
Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...
-
Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...
-
Event features discussions about health care industry trends, best practices and innovations
PA Sub-Categories: Specialty drugs Prime Article: Stories -
Home Our solutions Modern technology MyRxInsights Our advanced analytics platform helps boost your clinical impact and drive down costs by delivering descriptive, diagnostic, predictive and...
-
When you fill your specialty prescription, we automatically enroll you in our Care Specialists program. Our care specialists are pharmacists and nurses who are specially trained in your condition....
-
Eyebrow High-Cost Therapy Profile: August 2024 Detailed information about intravenous (IV) linvoseltamab Oncology Linvoseltamab, intravenous (IV) Regeneron Pharmaceuticals Proposed indications...